Clinical trial: Ulcerative colitis maintenance treatment with 5-ASA: A 1-year, randomized multicentre study comparing MMX® with Asacol®

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 9, 2009, Pages 908-918

  Prantera, C ^a   Kohn, A ^a   Campieri, M ^a   Caprilli, R ^b   Cottone, M ^c   Pallone, F ^d   Savarino, V ^e   Sturniolo, G C ^f   Vecchi, M ^e   Ardia, A ^g   Bellinvia, S ^h  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

^d VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^e Osp Cervello ^*  (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h GIULIANI S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; MESAVANCOL; MMX; MMX MULTI MATRIX SYSTEM; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOCHEZIA; HEMORRHOID; HUMAN; KIDNEY COLIC; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; NEPHROLITHIASIS; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PERIRENAL ABSCESS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT DURATION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PATIENT COMPLIANCE; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349675865     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04117.x     Document Type: Article

References (31)

1. Kornbluth A, Sachar DB. Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 99 : 1371 1385.
2. Travis SPL, Strange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008 2 : 24 62.
3. Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev 2005 57 : 281 302.
4. Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987 28 : 196 200.
5. Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006 24 : 465 474.
6. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003 1 : 170 173.
7. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001 96 : 2929 2933.
8. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003 18 : 191 198.
9. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982 4 : 333 336.
10. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003 114 : 39 43.
11. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005 11 : 421 427.
12. TM mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv Ther 2007 24 : 826 840.
13. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007 132 : 66 75.
14. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007 5 : 95 102.
15. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomized trial of once- or twice-daily MMX™ mesalamine for maintenance of remission in ulcerative colitis. Gut 2008 57 : 893 902.
16. Ardizzone S, Petrillo M, Imbesi V, et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999 13 : 373 379.
17. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005 21 : 1111 1119.
18. Paoluzi P, d'Albasio G, Pera A, et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis 2002 34 : 787 793.
19. Rubin DT, Siegel CA, Kane SV, et al. Living with ulcerative colitis: differing perceptions of patients and gastroenterologists. Inflamm Bowel Dis 2008 14 : S22.
20. Sewitch MJ, Abrahamowicz M, Bitton A, et al. Psychosocial correlates of patient-physician discordance in inflammatory bowel disease. Am J Gastroenterol 2002 97 : 2174 2183.
21. Sewitch MJ, Abrahamowicz M, Dobkin PL, et al. Measuring differences between patients' and physicians' health perceptions: the patient-physician discordance scale. J Behav Med 2003 26 : 245 264.
22. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996 124 : 204 211.
23. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006 23 : 577 585.
24. Bernklev T, Jahnsen J, Aadland E, et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol 2004 39 : 365 373.
25. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005 11 : 488 496.
26. Han SW, McColl E, Barton JR, et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis 2005 11 : 24 34.
27. Janke KH, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005 11 : 272 286. (Pubitemid 40439682)
28. Saibeni S, Cortinovis I, Beretta L, et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology 2005 52 : 509 515.
29. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis 2006 12 : 1107 1113.
30. Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007 15 : 257 263.
31. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006 19 : 1190 1196.